Codiak BioSciences, Inc. (CDAK)
| Market Cap | 87.50M |
| Revenue (ttm) | 22.45M |
| Net Income (ttm) | -34.88M |
| Shares Out | 22.49M |
| EPS (ttm) | -1.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,761,395 |
| Open | 3.82 |
| Previous Close | 3.81 |
| Day's Range | 3.32 - 4.02 |
| 52-Week Range | 2.21 - 22.95 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 11.56 (+197.2%) |
| Earnings Date | Aug 4, 2022 |
About CDAK
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vacci... [Read more...]
Financial Performance
In 2021, CDAK's revenue was $22.94 million, an increase of 686.79% compared to the previous year's $2.92 million. Losses were -$37.16 million, -59.46% less than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CDAK stock is "Buy." The 12-month stock price forecast is 11.56, which is an increase of 197.17% from the latest price.
News
Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy
Engineering exosomes to encapsulate AAV results in increased yield, resists antibody neutralization in vitro and retains transduction ability Engineering exosomes to encapsulate AAV results in increased...
Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress
– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 –
Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
– Experienced oncology drug developer with more than two decades advancing treatments for solid tumors and hematologic malignancies joins Codiak leadership – – Experienced oncology drug developer with m...
Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine
– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo –
Codiak's exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloi...
– New preclinical data presented at AACR Annual Meeting 2022 –
Codiak BioSciences, Inc. (CDAK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Codiak BioSciences, Inc. (CDAK), indicating that the stock has found support. This, combined with an upward trend in earnings e...
Codiak BioSciences, Inc. (CDAK) Reports Q4 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 27.18% and 69.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
– Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 –
Data from Codiak's exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic ...
– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models –
Codiak BioSciences, Inc. (CDAK) Stock Jumps 18.2%: Will It Continue to Soar?
Codiak BioSciences, Inc. (CDAK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the...
Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new ...
Codiak's COVID-19 Vaccine Hopeful Shows Potential In Preclinical Study
Codiak BioSciences Inc (NASDAQ: CDAK) announced new preclinical data from its exoVACC exosome-based vaccine platform. The data showed that the COVID-19 vaccine candidate generated a comprehensive immun...
Codiak's Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in vivo, Supporting the Potential fo...
Preclinical data at World Vaccine & Immunotherapy Congress 2021 show broad immunogenicity and neutralization against multiple SARS-CoV-2 variants Preclinical data at World Vaccine & Immunotherapy Congre...
Codiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new ...
Codiak BioSciences Announces FDA Clearance of IND for exoASO™-STAT6; Patient Dosing Expected 1H 2022
– Codiak's first engineered exosome therapeutic candidate for systemic administration –
Codiak BioSciences' Exosome Candidate Shows Tumor Shrinkage In Early Study
Codiak BioSciences Inc (NASDAQ: CDAK) announced initial data for exoSTING currently in a Phase 1/2 trial as a single agent for the treatment of multiple solid tumors. ExoSTING is an engineered exosome t...
Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Ev...
– exoSTING resulted in localized STING pathway activation and dose-dependent immune activation –
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Misses Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of -2.11% and -59.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...
Codiak BioSciences Reports Third Quarter 2021 Financial Results and Recent Operational Progress
– Announced strategic long-term exosome manufacturing collaboration with Lonza –
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, announced today the acquisition of an ex...
Codiak to Present Preclinical Data Demonstrating New Potential Therapeutic Applications of Engineered Exosomes at the...
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutic...
Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors
CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutic...
Codiak BioSciences Reports Second Quarter 2021 Financial Results and Operational Progress
– Initial safety and PK/PD data from Phase 1/2 study of exoSTING™ now expected in the fourth quarter of 2021 –
Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutic...